Ismael García-Moguel

Ismael García-Moguel

Auto-generated profile, based on publicly available information

Ismael García-Moguel

Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2024 in Journal of Investigational Allergology and Clinical Immunology
Verified
Journal Article
Open access
JMJ C Miralles-López
J C Miralles-López
DADarío Antolín-Amérigo2
Darío Antolín-Amérigo2
IGI García-Moguel
I García-Moguel
JDJavier Dominguez-Ortega
Javier Dominguez-Ortega
JDJ Delgado-Romero
J Delgado-Romero
SQSantiago Quirce
Santiago Quirce
Asthma is one of the most common chronic diseases and is estimated to be severe in 3%-10% of affected patients. There is a need for additional biologic treatments that are highly efficacious across the spectrum of severe uncontrolled asthma. Currently available drugs inhibit 1 or 2 specific cytokines or IgE antibodies and thus only partially suppress the complex type 2 (T2) inflammatory cascade. Biologics argeting more upstream molecules in the pathophysiological pathway of asthma could treat asthma more effectively. Tezepelumab is a human monoclonal immunoglobulin G2λ antibody that targets the cytokine thymic stromal lymphopoietin (TSLP). It is the first marketed biologic against an epithelial cell–derived cytokine, preventing binding of TSLP to its receptor and reducing the immune stimuli that TSLP can trigger in different asthma endotypes. Tezepelumab reduces downstream biomarkers of inflammation, such as blood and airway eosinophils, FeNO, IgE, IL-5, and IL-13. Tezepelumab provides a clinical benefit in severe asthma, reducing the annualized asthma exacerbation rate in patients with either high or low levels of biomarkers of T2 inflammation, although the effect is greater among those with high levels. The drug has been shown to improve asthma control, quality of life, and lung function and reduce airway hyperresponsiveness. Therefore, tezepelumab can be used across the spectrum of patients with severe uncontrolled asthma, especially in T2-high patients. This review includes a positioning statement by the authors, all of whom are members of the SEAIC Asthma Committee.

1 May 2022 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
PDF file
IGIsmael García-Moguel
Ismael García-Moguel
ARAna Rosado
Ana Rosado
AGAída Gómez-Cardeñosa
Aída Gómez-Cardeñosa
MGMar Gandolfo-Cano
Mar Gandolfo-Cano
TETeresa Robledo Echarren
Teresa Robledo Echarren
JDJavier Domínguez-Ortega
Javier Domínguez-Ortega
Introduction: The increase in drugs available for severe uncontrolled asthma and the lifestyle of these patients make it necessary to implement self-administration programs of these therapies at home. Benralizumab, a monoclonal antibody targeting IL5R, was authorized in Spain for poorly controlled severe eosinophilic asthma. The possibility of administration at home was approved in March 2020 in Spain. The aim of the Auto-Benra study was to evaluate the usability and satisfaction of the benralizumab prefilled syringe and autoinjector and assessing the effectivity of these devices in uncontrolled severe eosinophilic asthma (SEA) in home-self administration. Methods: This is a retrospective, observational multicenter study uncontrolled SEA patients treated with benralizumab at least with 3 doses self-administered at home before April 30, 2021. Reliability and satisfaction with benralizumab at home were evaluated with subcutaneous administration assessment questionnaire (SQAAQ) and visual analogic scales (VAS). Effectiveness was evaluated in all patients with asthma control test (ACT), Mini Asthma Quality of Life Questionnaire (MiniAQLQ), annual exacerbation rate, oral corticosteroid treatment (OCS) and asthma-related hospitalizations and emergency visits. Results: Fifty-four patients across 9 hospitals in Spain were included. The mean SQAAQ score was 6.89 (± 0.16) points. Patients and their caregivers and doctors report excellent satisfaction by VAS, with no differences between benralizumab devices used (prefilled syringe and autoinjector). Severe exacerbation rate decreased by 65% (p = 0.0007) after benralizumab treatment. ACT score improved on average 6.27 ± 5.35 points (p < 0.0001) and the mean MiniAQLQ increased up to 1.58 ± 1.47 points (p < 0.0001). Twenty-four patients were OCS-dependent and at the end of study 14 patients get complete OCS withdrawal. Conclusion: AUTO-BENRA study supports the use of benralizumab at home given the excellent results of satisfaction and usability by patients and their caregivers.

1 March 2019 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
IGIsmael García-Moguel
Ismael García-Moguel
IBIrina Bobolea
Irina Bobolea
MPMaria Carmen Diéguez Pastor
Maria Carmen Diéguez Pastor
GMGuillermo López-Arranz Monge
Guillermo López-Arranz Monge
RJRuth Barranco Jimenez
Ruth Barranco Jimenez

1 February 2022 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
PDF file
AMAlicia Habernau Mena
Alicia Habernau Mena
IGIsmael García-Moguel
Ismael García-Moguel
MGMaría Vazquez de la Torre Gaspar
María Vazquez de la Torre Gaspar
VMVictoria Mugica
Victoria Mugica
MIMaria Isabel Alvarado Izquierdo
Maria Isabel Alvarado Izquierdo
JDJavier Dominguez-Ortega
Javier Dominguez-Ortega
Purpose: The acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has had a high impact on patients with chronic diseases. In the literature, there are different perspectives on asthma as comorbidity or risk factor on COVID-19 severity. Patients and Methods: The aim of this retrospective study across 13 allergy departments in Spain was to determine the severity of COVID-19 in asthmatic adults followed in allergy departments and its relationship with atopy, clinical and demographic characteristics, phenotypes and laboratory data. In addition, lung function test and asthma control test (ACT) before and after COVID-19 were analyzed. Data was obtained from electronic medical records from March 2020 to April 2021. Results: Two hundred one asthmatic patients were diagnosed with COVID-19 infection by validated detection test. About 30% of the patients were admitted for bilateral pneumonia. Advanced age, elevated D-dimer, lower numbers of lymphocytes and eosinophils, heart diseases and hypertension were associated with severe COVID-19. Allergic and mixed allergic/eosinophilic phenotype and their biomarkers (total IgE, aeroallergens sensitizations, allergic rhinitis, and blood eosinophilia) were related to fewer hospital admissions. Poor control and lower forced expiratory volume in the first second (FEV1) were related to worse prognosis of COVID-19. Conclusion: Asthmatic patients with allergic and eosinophilic phenotype have a better evolution of COVID-19 and lower risk of admissions. Older patients, cardiovascular comorbidities, AERD and eosinopenia are related to severity COVID-19.

1 May 2026 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
PDF file
JDJavier Dominguez-Ortega
Javier Dominguez-Ortega
GLGabriela Leon-Zambrana
Gabriela Leon-Zambrana
José Antonio CañasJosé Antonio Cañas
José Antonio Cañas
IGIsmael García-Moguel
Ismael García-Moguel
JIJuan Manuel Igea
Juan Manuel Igea
Victoria Del PozoVictoria Del Pozo
Victoria Del Pozo
Background: Accurate inflammatory phenotyping in asthma remains challenging. Nasal cytology has emerged as a potential non-invasive tool to assess airway inflammation in asthma. However, its relationship with lower airway inflammation and systemic biomarkers remains unclear, particularly in severe asthma (SA). Objective: To evaluate whether a multi-compartment approach could improve the characterisation of type 2 inflammation and the relationship between nasal cytology, induced sputum, and systemic inflammatory biomarkers in patients with severe asthma. Methods: In this cross-sectional exploratory BRISA study, twenty-two patients with SA underwent nasal cytology by mucosal scraping, induced sputum analysis, and serum biomarker assessment (periostin, eosinophil cationic protein, thymic stromal lymphopoietin, dipeptidyl peptidase-4, and total IgE). Patients were stratified according to blood eosinophil count (BEC < 300 vs ≥ 300 cells/μL). Correlations between compartments and associations with clinical and inflammatory variables were analysed. Results: Higher blood eosinophil counts were associated with worse lung function, increased exacerbations, and higher serum periostin levels. Valid induced sputum samples were obtained in 16 patients: 7 eosinophilic, 3 neutrophilic, 2 mixed eosinophilic-neutrophilic and 4 paucigranulocytic. Nasal cytology predominantly showed limited agreement with induced sputum inflammatory phenotypes. Serum TSLP, DPP4, and IgE also showed an upward trend in patients with higher blood eosinophil counts, although these differences were not statistically significant. Correlation analysis demonstrated a significant positive association between sputum and blood eosinophils, as well as between blood eosinophils and serum periostin. A strong positive correlation was also observed between serum eotaxin and TSLP. Conclusion: Nasal cytology alone cannot replace induced sputum for inflammatory phenotyping in SA, although it may provide complementary information on upper airway inflammation. Among the evaluated systemic biomarkers, periostin emerged as the most consistent marker associated with blood eosinophilia, while other biomarkers showed only non-significant trends. Further studies are needed to validate the role of combined biomarkers in predicting airway inflammation.

20 April 2025 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
AEAlicia Enríquez‐Matas
Alicia Enríquez‐Matas
BMBeatriz Moya
Beatriz Moya
TCTatiana Navarro Cascales
Tatiana Navarro Cascales
CFCarmen Romero Ferreiro
Carmen Romero Ferreiro
AAAna Alastruey‐Izquierdo
Ana Alastruey‐Izquierdo
CRConsuelo Fernández Rodríguez
Consuelo Fernández Rodríguez